TLR9 and graft versus host disease: Clinical evidence has also demonstrated that the donor homozygous recessive genotype of the TLR9 1635A/G SNP was associated with a higher incidence of CMV reactivation and yielded a protective effect against acute graft versus host disease in allo-HSCT recipients [12].